Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CIML NK cell therapy + interleukin-2
- Development stage
- Unknown
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
This combination immunotherapy consists of autologous cytokine-induced memory-like (CIML) natural killer (NK) cells and low-dose interleukin-2 (IL-2). The CIML NK cells are generated by ex vivo activation of a patient's own NK cells with a cocktail of cytokines (typically IL-12, IL-15, and IL-18), which induces a stable memory-like phenotype characterized by enhanced effector function and longevity. Following lymphodepleting chemotherapy, these cells are re-infused into the patient. Low-dose IL-2 (aldesleukin) is subsequently administered to promote the expansion, survival, and anti-tumor activity of the infused NK cells. This approach is being investigated by the Dana-Farber Cancer Institute for the treatment of advanced clear cell renal cell carcinoma and urothelial carcinoma.
- Other names
- Cytokine-Induced Memory-like Natural Killer Cells + IL-2CIML NK cells + aldesleukinCIML NK cell therapy + IL-2
Beyond the preview
Go deeper on CIML NK cell therapy + interleukin-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CIML NK cell therapy + interleukin-2.